Silence Therapeutics plc (NASDAQ: SLN) Stock Competitors & Peer Comparison

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, VRTX has a market cap of 127.2B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while VRTX trades at $501.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas VRTX's P/E ratio is 26.38. In terms of profitability, SLN's ROE is -1.07%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, SLN is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check VRTX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, MRNA has a market cap of 90.6B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while MRNA trades at $226.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas MRNA's P/E ratio is -27.84. In terms of profitability, SLN's ROE is -1.07%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, SLN is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for SLN.Check MRNA's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, REGN has a market cap of 80.5B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while REGN trades at $782.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas REGN's P/E ratio is 17.14. In terms of profitability, SLN's ROE is -1.07%, compared to REGN's ROE of +0.14%. Regarding short-term risk, SLN is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for SLN.Check REGN's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas VRNA's P/E ratio is -102.80. In terms of profitability, SLN's ROE is -1.07%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, SLN is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for SLN.Check VRNA's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ARGX has a market cap of 51.8B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ARGX trades at $825.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ARGX's P/E ratio is 29.80. In terms of profitability, SLN's ROE is -1.07%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, SLN is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check ARGX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SLN's ROE is -1.07%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SLN is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for SLN.Check SGEN's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ONC has a market cap of 39.6B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ONC trades at $370.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ONC's P/E ratio is 65.17. In terms of profitability, SLN's ROE is -1.07%, compared to ONC's ROE of +0.14%. Regarding short-term risk, SLN is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for SLN.Check ONC's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, RVMDW has a market cap of 39.5B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while RVMDW trades at $8.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas RVMDW's P/E ratio is -0.99. In terms of profitability, SLN's ROE is -1.07%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, SLN is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for SLN.Check RVMDW's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, RVMD has a market cap of 39B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while RVMD trades at $182.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas RVMD's P/E ratio is -20.65. In terms of profitability, SLN's ROE is -1.07%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, SLN is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for SLN.Check RVMD's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ALNY has a market cap of 31.2B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ALNY trades at $233.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ALNY's P/E ratio is 42.03. In terms of profitability, SLN's ROE is -1.07%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, SLN is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for SLN.Check ALNY's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ROIV has a market cap of 25.1B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ROIV trades at $34.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ROIV's P/E ratio is -33.01. In terms of profitability, SLN's ROE is -1.07%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, SLN is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for SLN.Check ROIV's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, GMAB has a market cap of 23.7B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while GMAB trades at $38.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas GMAB's P/E ratio is 29.01. In terms of profitability, SLN's ROE is -1.07%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, SLN is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for SLN.Check GMAB's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, UTHR has a market cap of 23.3B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while UTHR trades at $543.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas UTHR's P/E ratio is 19.43. In terms of profitability, SLN's ROE is -1.07%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, SLN is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for SLN.Check UTHR's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, INCY has a market cap of 23B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while INCY trades at $113.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas INCY's P/E ratio is 15.22. In terms of profitability, SLN's ROE is -1.07%, compared to INCY's ROE of +0.30%. Regarding short-term risk, SLN is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for SLN.Check INCY's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, BNTX has a market cap of 22.4B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while BNTX trades at $89.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas BNTX's P/E ratio is -11.56. In terms of profitability, SLN's ROE is -1.07%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, SLN is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check BNTX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, INSM has a market cap of 20.8B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while INSM trades at $95.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas INSM's P/E ratio is -23.18. In terms of profitability, SLN's ROE is -1.07%, compared to INSM's ROE of -1.11%. Regarding short-term risk, SLN is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for SLN.Check INSM's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SLN's ROE is -1.07%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, SLN is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for SLN.Check BGNE's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SLN's ROE is -1.07%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, SLN is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for SLN.Check DNA-WT's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, EXEL has a market cap of 15.8B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while EXEL trades at $62.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas EXEL's P/E ratio is 17.91. In terms of profitability, SLN's ROE is -1.07%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, SLN is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for SLN.Check EXEL's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ASND has a market cap of 14.3B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ASND trades at $229.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ASND's P/E ratio is -94.94. In terms of profitability, SLN's ROE is -1.07%, compared to ASND's ROE of +1.90%. Regarding short-term risk, SLN is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for SLN.Check ASND's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, NBIX has a market cap of 13.9B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while NBIX trades at $136.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas NBIX's P/E ratio is 19.79. In terms of profitability, SLN's ROE is -1.07%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, SLN is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check NBIX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, HALO has a market cap of 13.9B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while HALO trades at $122.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas HALO's P/E ratio is 22.85. In terms of profitability, SLN's ROE is -1.07%, compared to HALO's ROE of +1.81%. Regarding short-term risk, SLN is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for SLN.Check HALO's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, JAZZ has a market cap of 13.5B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while JAZZ trades at $208.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas JAZZ's P/E ratio is 7.77. In terms of profitability, SLN's ROE is -1.07%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, SLN is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for SLN.Check JAZZ's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, BBIO has a market cap of 13.3B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while BBIO trades at $67.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas BBIO's P/E ratio is -18.17. In terms of profitability, SLN's ROE is -1.07%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, SLN is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for SLN.Check BBIO's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SLN's ROE is -1.07%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SLN is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for SLN.Check KRTX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, SMMT has a market cap of 12.4B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while SMMT trades at $15.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas SMMT's P/E ratio is -13.90. In terms of profitability, SLN's ROE is -1.07%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, SLN is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for SLN.Check SMMT's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while TECH trades at $72.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas TECH's P/E ratio is 37.37. In terms of profitability, SLN's ROE is -1.07%, compared to TECH's ROE of +0.09%. Regarding short-term risk, SLN is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for SLN.Check TECH's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas RNAM's P/E ratio is -17.39. In terms of profitability, SLN's ROE is -1.07%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, SLN is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for SLN.Check RNAM's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while BMRN trades at $54.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas BMRN's P/E ratio is 26.28. In terms of profitability, SLN's ROE is -1.07%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, SLN is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for SLN.Check BMRN's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, MDGL has a market cap of 10.3B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while MDGL trades at $447.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas MDGL's P/E ratio is -34.92. In terms of profitability, SLN's ROE is -1.07%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, SLN is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for SLN.Check MDGL's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, PCVX has a market cap of 9.8B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while PCVX trades at $63.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas PCVX's P/E ratio is -8.35. In terms of profitability, SLN's ROE is -1.07%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, SLN is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check PCVX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SLN's ROE is -1.07%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SLN is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for SLN.Check RXDX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, KRYS has a market cap of 9.5B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while KRYS trades at $320.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas KRYS's P/E ratio is 40.13. In terms of profitability, SLN's ROE is -1.07%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, SLN is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for SLN.Check KRYS's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, TWST has a market cap of 9.2B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while TWST trades at $139.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas TWST's P/E ratio is -62.95. In terms of profitability, SLN's ROE is -1.07%, compared to TWST's ROE of -0.30%. Regarding short-term risk, SLN is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for SLN.Check TWST's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas NUVL's P/E ratio is -21.79. In terms of profitability, SLN's ROE is -1.07%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, SLN is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for SLN.Check NUVL's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, TXG has a market cap of 9.1B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while TXG trades at $69.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas TXG's P/E ratio is -118.46. In terms of profitability, SLN's ROE is -1.07%, compared to TXG's ROE of -0.09%. Regarding short-term risk, SLN is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for SLN.Check TXG's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas CRNX's P/E ratio is -16.86. In terms of profitability, SLN's ROE is -1.07%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, SLN is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for SLN.Check CRNX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while IBRX trades at $8.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas IBRX's P/E ratio is -8.68. In terms of profitability, SLN's ROE is -1.07%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, SLN is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check IBRX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, KYMR has a market cap of 8.9B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while KYMR trades at $108.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas KYMR's P/E ratio is -33.77. In terms of profitability, SLN's ROE is -1.07%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, SLN is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for SLN.Check KYMR's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SLN's ROE is -1.07%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, SLN is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for SLN.Check IMGN's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, CYTK has a market cap of 8.7B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while CYTK trades at $62.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas CYTK's P/E ratio is -8.68. In terms of profitability, SLN's ROE is -1.07%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, SLN is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for SLN.Check CYTK's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while PTGX trades at $134.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas PTGX's P/E ratio is 130.52. In terms of profitability, SLN's ROE is -1.07%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, SLN is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check PTGX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, CAI has a market cap of 8.7B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while CAI trades at $30.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas CAI's P/E ratio is 86.26. In terms of profitability, SLN's ROE is -1.07%, compared to CAI's ROE of +0.19%. Regarding short-term risk, SLN is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for SLN.Check CAI's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas APGE's P/E ratio is -31.19. In terms of profitability, SLN's ROE is -1.07%, compared to APGE's ROE of -0.30%. Regarding short-term risk, SLN is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for SLN.Check APGE's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas BPMC's P/E ratio is -51.58. In terms of profitability, SLN's ROE is -1.07%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, SLN is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for SLN.Check BPMC's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas CERE's P/E ratio is -16.47. In terms of profitability, SLN's ROE is -1.07%, compared to CERE's ROE of -0.72%. Regarding short-term risk, SLN is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for SLN.Check CERE's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, AXSM has a market cap of 8.2B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while AXSM trades at $155.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas AXSM's P/E ratio is -40.69. In terms of profitability, SLN's ROE is -1.07%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, SLN is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for SLN.Check AXSM's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, TGTX has a market cap of 8.2B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while TGTX trades at $53.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas TGTX's P/E ratio is 19.31. In terms of profitability, SLN's ROE is -1.07%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, SLN is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check TGTX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ARWR has a market cap of 8.1B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ARWR trades at $57.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ARWR's P/E ratio is -25.42. In terms of profitability, SLN's ROE is -1.07%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, SLN is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for SLN.Check ARWR's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, SYRE has a market cap of 7.8B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while SYRE trades at $84.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas SYRE's P/E ratio is -43.41. In terms of profitability, SLN's ROE is -1.07%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, SLN is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for SLN.Check SYRE's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ABVX has a market cap of 7.6B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ABVX trades at $87.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ABVX's P/E ratio is -14.35. In terms of profitability, SLN's ROE is -1.07%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, SLN is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check ABVX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas MTSR's P/E ratio is -23.58. In terms of profitability, SLN's ROE is -1.07%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, SLN is less volatile compared to MTSR. This indicates lower risk in terms of short-term price fluctuations for SLN.Check MTSR's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, IONS has a market cap of 7.4B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while IONS trades at $44.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas IONS's P/E ratio is -13.58. In terms of profitability, SLN's ROE is -1.07%, compared to IONS's ROE of -1.11%. Regarding short-term risk, SLN is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for SLN.Check IONS's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, PRAX has a market cap of 7.3B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while PRAX trades at $260.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas PRAX's P/E ratio is -20.12. In terms of profitability, SLN's ROE is -1.07%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, SLN is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check PRAX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas MRUS's P/E ratio is -17.05. In terms of profitability, SLN's ROE is -1.07%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, SLN is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for SLN.Check MRUS's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ACLX's P/E ratio is -28.27. In terms of profitability, SLN's ROE is -1.07%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, SLN is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for SLN.Check ACLX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas RETA's P/E ratio is -66.29. In terms of profitability, SLN's ROE is -1.07%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SLN is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for SLN.Check RETA's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, IOVA has a market cap of 6.4B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while IOVA trades at $14.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas IOVA's P/E ratio is -19.47. In terms of profitability, SLN's ROE is -1.07%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, SLN is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for SLN.Check IOVA's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas CNTA's P/E ratio is -22.63. In terms of profitability, SLN's ROE is -1.07%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, SLN is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for SLN.Check CNTA's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas TERN's P/E ratio is -51.41. In terms of profitability, SLN's ROE is -1.07%, compared to TERN's ROE of -0.14%. Regarding short-term risk, SLN is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for SLN.Check TERN's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, RYTM has a market cap of 6.1B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while RYTM trades at $88.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas RYTM's P/E ratio is -28.37. In terms of profitability, SLN's ROE is -1.07%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, SLN is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for SLN.Check RYTM's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, BLTE has a market cap of 6B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while BLTE trades at $147.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas BLTE's P/E ratio is -79.05. In terms of profitability, SLN's ROE is -1.07%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, SLN is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for SLN.Check BLTE's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while LGND trades at $297.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas LGND's P/E ratio is 32.64. In terms of profitability, SLN's ROE is -1.07%, compared to LGND's ROE of +0.20%. Regarding short-term risk, SLN is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for SLN.Check LGND's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, KOD has a market cap of 5.7B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while KOD trades at $91.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas KOD's P/E ratio is -21.91. In terms of profitability, SLN's ROE is -1.07%, compared to KOD's ROE of -2.73%. Regarding short-term risk, SLN is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for SLN.Check KOD's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, IMVT has a market cap of 5.7B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while IMVT trades at $27.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas IMVT's P/E ratio is -9.79. In terms of profitability, SLN's ROE is -1.07%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, SLN is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for SLN.Check IMVT's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas CDTX's P/E ratio is -19.77. In terms of profitability, SLN's ROE is -1.07%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, SLN is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for SLN.Check CDTX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SLN's ROE is -1.07%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SLN is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for SLN.Check ABCM's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SLN's ROE is -1.07%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SLN is less volatile compared to ISEE. This indicates lower risk in terms of short-term price fluctuations for SLN.Check ISEE's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, MIRM has a market cap of 5.3B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while MIRM trades at $82.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas MIRM's P/E ratio is -5.65. In terms of profitability, SLN's ROE is -1.07%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, SLN is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for SLN.Check MIRM's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, CGON has a market cap of 5.3B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while CGON trades at $59.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas CGON's P/E ratio is -22.29. In terms of profitability, SLN's ROE is -1.07%, compared to CGON's ROE of -0.25%. Regarding short-term risk, SLN is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for SLN.Check CGON's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas APLS's P/E ratio is 38.35. In terms of profitability, SLN's ROE is -1.07%, compared to APLS's ROE of +0.40%. Regarding short-term risk, SLN is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for SLN.Check APLS's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, COGT has a market cap of 5.2B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while COGT trades at $30.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas COGT's P/E ratio is -14.22. In terms of profitability, SLN's ROE is -1.07%, compared to COGT's ROE of -0.73%. Regarding short-term risk, SLN is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for SLN.Check COGT's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, PTCT has a market cap of 5.1B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while PTCT trades at $61.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas PTCT's P/E ratio is -26.41. In terms of profitability, SLN's ROE is -1.07%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, SLN is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for SLN.Check PTCT's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, MANE has a market cap of 5.1B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while MANE trades at $122.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas MANE's P/E ratio is -38.96. In terms of profitability, SLN's ROE is -1.07%, compared to MANE's ROE of -0.38%. Regarding short-term risk, SLN is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for SLN.Check MANE's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ORKA has a market cap of 4.9B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ORKA trades at $74.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ORKA's P/E ratio is -38.39. In terms of profitability, SLN's ROE is -1.07%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, SLN is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for SLN.Check ORKA's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, SRRK has a market cap of 4.9B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while SRRK trades at $40.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas SRRK's P/E ratio is -11.66. In terms of profitability, SLN's ROE is -1.07%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, SLN is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for SLN.Check SRRK's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while CRSP trades at $50.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas CRSP's P/E ratio is -10.51. In terms of profitability, SLN's ROE is -1.07%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, SLN is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for SLN.Check CRSP's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ERAS has a market cap of 4.8B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ERAS trades at $13.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ERAS's P/E ratio is -14.65. In terms of profitability, SLN's ROE is -1.07%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, SLN is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for SLN.Check ERAS's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, TVTX has a market cap of 4.8B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while TVTX trades at $50.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas TVTX's P/E ratio is -112.20. In terms of profitability, SLN's ROE is -1.07%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, SLN is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check TVTX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas FOLD's P/E ratio is -161.00. In terms of profitability, SLN's ROE is -1.07%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, SLN is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for SLN.Check FOLD's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas AKRO's P/E ratio is -14.57. In terms of profitability, SLN's ROE is -1.07%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, SLN is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for SLN.Check AKRO's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SLN's ROE is -1.07%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, SLN is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for SLN.Check ALPN's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, DFTX has a market cap of 4.4B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while DFTX trades at $32.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas DFTX's P/E ratio is N/A. In terms of profitability, SLN's ROE is -1.07%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, SLN is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check DFTX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas OPT's P/E ratio is -1.52. In terms of profitability, SLN's ROE is -1.07%, compared to OPT's ROE of +1.18%. Regarding short-term risk, SLN is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for SLN.Check OPT's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas PRTC's P/E ratio is -3.78. In terms of profitability, SLN's ROE is -1.07%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, SLN is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for SLN.Check PRTC's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, DNTH has a market cap of 4.2B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while DNTH trades at $74.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas DNTH's P/E ratio is -17.96. In terms of profitability, SLN's ROE is -1.07%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, SLN is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for SLN.Check DNTH's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SLN's ROE is -1.07%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SLN is less volatile compared to MRTX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check MRTX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while EWTX trades at $37.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas EWTX's P/E ratio is -20.49. In terms of profitability, SLN's ROE is -1.07%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, SLN is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check EWTX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ARQT has a market cap of 4B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ARQT trades at $31.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ARQT's P/E ratio is 151.83. In terms of profitability, SLN's ROE is -1.07%, compared to ARQT's ROE of +0.15%. Regarding short-term risk, SLN is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for SLN.Check ARQT's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while TNGX trades at $23.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas TNGX's P/E ratio is -28.34. In terms of profitability, SLN's ROE is -1.07%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, SLN is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check TNGX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ABCL trades at $11.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ABCL's P/E ratio is -22.11. In terms of profitability, SLN's ROE is -1.07%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, SLN is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for SLN.Check ABCL's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas CPRX's P/E ratio is 17.49. In terms of profitability, SLN's ROE is -1.07%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, SLN is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for SLN.Check CPRX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, ADPT has a market cap of 3.8B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while ADPT trades at $23.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas ADPT's P/E ratio is -58.41. In terms of profitability, SLN's ROE is -1.07%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, SLN is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for SLN.Check ADPT's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SLN's ROE is -1.07%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SLN is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for SLN.Check RYZB's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, RLAY has a market cap of 3.7B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while RLAY trades at $17.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas RLAY's P/E ratio is -10.89. In terms of profitability, SLN's ROE is -1.07%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, SLN is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for SLN.Check RLAY's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SLN's ROE is -1.07%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, SLN is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for SLN.Check CBAY's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while TLX trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas TLX's P/E ratio is 112.11. In terms of profitability, SLN's ROE is -1.07%, compared to TLX's ROE of +0.07%. Regarding short-term risk, SLN is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for SLN.Check TLX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas SWTX's P/E ratio is -13.78. In terms of profitability, SLN's ROE is -1.07%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, SLN is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for SLN.Check SWTX's competition here

Silence Therapeutics plc (NASDAQ: SLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SLN stands at 924.6M. In comparison, LEGN has a market cap of 3.4B. Regarding current trading prices, SLN is priced at $19.58 on the NASDAQ, while LEGN trades at $18.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SLN currently has a P/E ratio of -15.29, whereas LEGN's P/E ratio is -27.43. In terms of profitability, SLN's ROE is -1.07%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, SLN is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for SLN.Check LEGN's competition here